Talk:Innate Immunotherapeutics

Article presumes guilt
The article states that Collins warned his son that the clinical trials had failed, citing [15] NY Times article. The conversation was not recorded, and at this point only those two know what was said. The NYT piece does not claim to know what was said, only reports the fact that the son sold off shares soon afterwards.

Sealed indictment
Can this "sealed indictment" be used as an RS? It is linked via document helper in the New York Times August 8, 2018 article.Oceanflynn (talk) 19:17, 8 August 2018 (UTC)

There are statements in the indictment that I have not found elsewhere yet. For example, "The public announcement of these results caused the stock price of Innate to drop by 92%." "In his capacity as a member of Innate’s Board of Directors, Collins regularly had access to material, nonpublic information, including about MIS416 and the Drug Trial." "In or about October 2014, Innate initiated a Phase 2B clinical trial of its primary drug, MIS416. The Drug Trial was “blinded,” meaning that neither the administrators of the Drug Trial nor Innate’s leadership would know or be able to determine the results of the Drug Trial until it was completed, after which point data collected during the course of the Drug Trial would be unblinded and analyzed. Successful completion of the Drug Trial was a necessary prerequisite to the commercialization of MI8416. Because Innate had no other significant products in development, its stock price was tied to the success of MIS416."


 * That's a primary source, but a news outlet may cover it soon. Natureium (talk) 19:22, 8 August 2018 (UTC)